Klingman & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Klingman & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$297K	Buy	568 +21	+4%	+$10.8K	0.01%	327
2026 Q2	$272K	Buy	547 +18	+3%	+$7.98K	0.01%	285
2026 Q1	$236K	Buy	529 +64	+14%	+$29.8K	0.01%	298
2025 Q4	$211K	Buy	+465	New	+$200K	0.01%	312
2025 Q3	–	Sell	-466	Closed	-$207K	–	340
2025 Q2	$207K	Buy	+466	New	+$215K	0.01%	297

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

Klingman & Associates's VRTX Position: Q3 2026 in Review

Klingman & Associates increased its Vertex Pharmaceuticals (VRTX) stake by 3.8% in Q3 2026, buying an estimated $10.8K and bringing the position to 568 shares worth $297K. The position accounts for 0.01% of the portfolio, ranked #327.

Klingman & Associates first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. 445 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Klingman & Associates held 568 shares of Vertex Pharmaceuticals worth $297K as of Q3 2026.
Klingman & Associates bought 21 Vertex Pharmaceuticals shares in Q3 2026, an estimated $10.8K.
Vertex Pharmaceuticals made up 0.01% of Klingman & Associates's portfolio in Q3 2026, its #327 holding.
Klingman & Associates first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
445 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Klingman & Associates's 13F filing for Q3 2026, filed 20 Oct 2026.